Charles Schwab Investment Management Inc. Has $739.22 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Charles Schwab Investment Management Inc. increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,002,779 shares of the biopharmaceutical company’s stock after purchasing an additional 249,804 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Gilead Sciences were worth $739,217,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. HHM Wealth Advisors LLC increased its position in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares during the period. YANKCOM Partnership acquired a new position in shares of Gilead Sciences in the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the fourth quarter worth about $29,000. Crews Bank & Trust acquired a new stake in Gilead Sciences in the 4th quarter worth about $31,000. Finally, Stephens Consulting LLC boosted its holdings in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 293,356 shares of company stock worth $29,166,240 over the last three months. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $114.74 on Wednesday. The business’s 50-day moving average price is $98.28 and its 200-day moving average price is $90.74. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $117.39. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $143.00 billion, a price-to-earnings ratio of 310.11, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.75%. Gilead Sciences’s payout ratio is currently 854.05%.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a report on Thursday, February 13th. UBS Group increased their target price on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Finally, Truist Financial boosted their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research report on Friday, November 8th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $102.76.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.